XGX Pharma ApS: Financial statements 2017
CVR: 32289290
Source: annual report 2017, Danish Business Authority
01/01/2017 – 31/12/2017
XGX Pharma ApS (CVR 32289290) has filed annual accounts for 2017. In 2017, the company reported a gross profit of DKK 104,432 and a net result of DKK -189,057 compared with DKK 271,902 the year before. That is a decrease of 66% compared with the year before. Equity in the 2017 report amounted to DKK 32,469. The solvency ratio was 2.4%.
- Gross Profit
- DKK 104,432
- Profit/Loss
- DKK -189,057
- Equity
- DKK 32,469
- Total Assets
- DKK 1,345,888
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2017 | - | 104 t. | -189 t. | 32 t. | - |
| 2016 | - | 307 t. | 272 t. | 92 t. | - |
| 2015 | - | -33 t. | -35 t. | -180 t. | - |
| 2014 | - | - | -14 t. | -145 t. | - |
| 2013 | - | 145 t. | 145 t. | 130 t. | - |
Official annual report
Keep an eye on XGX Pharma ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2017
As of December 1, 2017, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of XGX Pharma ApS.
As of December 1, 2017, Jens-Nikolaj Schøier is registered as adm. dir. of XGX Pharma ApS.
As of December 1, 2017, Mohammad Sohail Asghar has stepped down as director of XGX Pharma ApS.
XGX Pharma ApS has published its annual report for 2016. Gross profit came to DKK 307,092, and the net result was DKK 271,902.
About XGX Pharma ApS
XGX Pharma ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2009. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Jens-Nikolaj Schøier. The board consists of Per Anders Larnholt (chair) and Johan Frödin. The company is owned by Unimedic Pharma AB. The company has 2 employees (2018). In 2025, the company reported a gross profit of DKK 32,338,381 and a net result of DKK 16,074,119 compared with DKK 4,453,433 the year before. Equity in the 2025 report amounted to DKK 30,787,180.